©The Author(s) 2025.
World J Gastrointest Oncol. Apr 15, 2025; 17(4): 104455
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.104455
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.104455
Table 2 Comparison of features between elderly (> 65) and non-elderly (< 65) patients with gastric adenocarcinoma, mean ± SD/n (%)
| Characteristic | Non-elderly (n = 59) | Elderly (n = 91) | Total (n = 150) | P value |
| Age | 56.1 ± 5.9 | 73.1 ± 6.6 | 66.4 ± 10.4 | < 0.001 |
| Gender | 0.571 | |||
| Female | 20 (34) | 35 (39) | 55 (37) | |
| Male | 39 (54) | 56 (61) | 95 (63) | |
| Observation duration (mo) | 22.1 ± 12.7 | 24.1 ± 14.4 | 23.3 ± 13.7 | 0.406 |
| Complaint at admission | ||||
| Dyspepsia | 40 (68) | 51 (56) | 91 (61) | 0.150 |
| Bleeding | 10 (17) | 24 (26) | 34 (23) | 0.178 |
| Constitutional | 7 (12) | 7 (8) | 14 (9) | 0.391 |
| Dysphagia | 8 (14) | 13 (14) | 21 (14) | 0.900 |
| Anemia | 7 (12) | 19 (21) | 26 (17) | 0.154 |
| Comorbidities | ||||
| HT | 10 (17) | 42 (46) | 52 (35) | < 0.001 |
| DM | 7 (12) | 14 (15) | 21 (14) | 0.392 |
| Cardiovascular | 7 (12) | 24 (26) | 31 (21) | 0.032 |
| AF | 0 (0) | 3 (3) | 3 (2) | 0.279 |
| CRD | 6 (10) | 13 (14) | 19 (13) | 0.459 |
| CVD | 4 (2) | 5 (6) | 6 (4) | 0.404 |
| CRF | 1 (2) | 3 (3) | 4 (3) | 0.999 |
| Hypothyroidism | 4 (7) | 0 (0) | 4 (3) | 0.022 |
| Stage | 0.064 | |||
| 1 | 3 (5) | 8 (10) | 11 (8) | |
| 2 | 5 (9) | 8 (10) | 3 (10) | |
| 3 | 30 (55) | 24 (32) | 54 (41) | |
| 4 | 17 (31) | 36 (48) | 53 (41) | |
| Metastasis | 17 (29) | 38 (42) | 55 (37) | 0.108 |
| Localization | 0.319 | |||
| Cardia | 36 (61) | 48 (53) | 84 (56) | |
| Non-cardia | 23 (39) | 43 (47) | 66 (44) | |
| Laboratory tests | ||||
| WBC, 103/UL | 8.3 ± 2.8 | 8.4 ± 3.7 | 8.3 ± 3.4 | 0.905 |
| Neutrophils, 103/UL | 5.5 ± 2.5 | 5.7 ± 2.8 | 5.6 ± 2.7 | 0.492 |
| Lym, 103/UL | 2.1 ± 0.8 | 1.9 ± 0.7 | 1.9 ± 0.8 | 0.125 |
| Monocytes, 103/UL | 0.5 ± 0.2 | 0.5 ± 0.1 | 0.5 ± 0.2 | 0.837 |
| Hemoglobin, g/dL | 12.8 ± 2.3 | 11.7 ± 2.9 | 12.8 ± 7.4 | 0.028 |
| RDW, % | 14.9 ± 2.3 | 15.8 ± 4.1 | 15.5 ± 3.6 | 0.101 |
| Platelet, 103/UL | 304 ± 116 | 295 ± 119 | 299 ± 117 | 0.662 |
| MPV, fL | 9.6 ± 1.1 | 9.4 ± 1.1 | 9.5 ± 1.1 | 0.386 |
| PDW, % | 16.1 ± 0.4 | 15.9 ± 0.4 | 16.0 ± 0.4 | 0.468 |
| CRP, mg/L | 15.9 ± 23.5 | 19.9 ± 30.1 | 18.4 ± 27.8 | 0.556 |
| Albumin, g/dL | 3.8 ± 0.5 | 3.6 ± 0.5 | 3.7 ± 0.5 | 0.014 |
| AST, IU/L | 23.8 ± 17.8 | 19.9 ± 10.1 | 21.4 ± 13.7 | 0.560 |
| ALT, IU/L | 22.1 ± 21.6 | 15.2 ± 8.9 | 17.9 ± 15.5 | 0.068 |
| Total bilirubin, mg/dL | 0.6 ± 0.4 | 0.6 ± 0.5 | 0.6 ± 0.4 | 0.822 |
| Creatinine, mg/dL | 0.82 ± 0.29 | 0.83 ± 0.25 | 0.83 ± 0.26 | 0.551 |
| BUN, mg/dL | 38.4 ± 22.3 | 44.4 ± 23.4 | 42.1 ± 23.1 | 0.009 |
| Sodium, mEq/L | 138.3 ± 3.1 | 138.1 ± 3.3 | 138.1 ± 3.2 | 0.373 |
| Potassium, mEq/L | 4.3 ± 0.4 | 4.2 ± 0.5 | 4.2 ± 0.5 | 0.607 |
| Indexes | ||||
| NLR | 3.1 ± 2.7 | 3.5 ± 3.1 | 3.3 ± 2.9 | 0.133 |
| PLR | 168.4 ± 97.9 | 174.7 ± 107.6 | 172.2 ± 103.6 | 0.560 |
| LMR | 4.4 ± 1.8 | 8.3 ± 37.9 | 6.7 ± 29.6 | 0.313 |
| SII | 1023 ± 1022 | 1119 ± 1530 | 1081 ± 1350 | 0.294 |
| Death | 13 (22) | 14 (15) | 27 (18) | 0.300 |
- Citation: Dolu S, Cengiz MB, Döngelli H, Gürbüz M, Arayici ME. Importance of hematological and inflammatory markers in the localization of gastric cancer. World J Gastrointest Oncol 2025; 17(4): 104455
- URL: https://www.wjgnet.com/1948-5204/full/v17/i4/104455.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i4.104455